COVID-19 Live Updates
Updated 21-JULY-2020 In partnership with ZS Associates, we connected with 1,250 patients globally to understand the impact of COVID-19 on clinical trials. See the infographic
Updated 21-JULY-2020 In partnership with ZS Associates, we connected with 1,250 patients globally to understand the impact of COVID-19 on clinical trials. See the infographic
Patients are more aware than ever of clinical research. Ensuring this increased awareness translates into more efficient trial enrollment will require adaptable strategies that reflect
Social distancing. Fear of infection. Major life disruptions. For most, these concerns are new, and related directly to COVID-19. But for people living with autoimmune
The coronavirus (COVID-19) pandemic is causing major disruptions to clinical trials, with one third of study sites anticipating closure and nearly 80% reporting at least
In 2018 Continuum Clinical conducted a social intelligence report—an analysis of online conversations centered around NASH. The report identified four key conversation themes: patient frustration,
Long before your study’s first randomization, before the first screening visit is scheduled, even before the very first patient is referred, sponsors have already invested
Goldman Sachs coined 2019 as the “Year of NASH.” They weren’t wrong, but it wasn’t all positive . . . this year, NASH is expected
An estimated 80% of clinical trials do not meet their patient enrollment goals1. Without enough patients to fill the trial, sponsors don’t have enough data
Without patients willing to enroll in clinical research, there would be no studies and therefore none of the potentially life-saving breakthroughs pharma is laboring to
There are countless challenges in implementing a global patient recruitment program—different cultures, multiple global gatekeepers, competing timelines and studies, multiple vendors, potentially varying protocols, and